AYOXXA Biosystems has appointed Dr Gerald Möller as an independent board director
Singapore: Germany and Singapore based biotech firm, AYOXXA Biosystems, has appointed Dr Gerald Möller as an independent board director and chairman of the board.
Dr Möller will guide AYOXXA's strategic expansion from life science research into disease specific applications, such as LUNARIS, AYOXXA's multiplexing technology that enables researchers in academia and the pharma industry to address the importance of proteomics in discovery and development of new medicines.
Dr Andreas Schmidt, CEO and Co-founder, AYOXXA Biosystems remarked, "I am excited about his commitment as new chairmen and investor of AYOXXA. What we see in genomics will be complemented by better understanding the power of proteomics. With Gerald Möller we found an experienced international leader to take up this challenge together with the board and management of AYOXXA.
"Over the last years I have been active in the fields of genomics and tissue phenomics and supported their important and growing impact in precision medicine. I am excited about the potential of the AYOXXA multiplexing platform which could become a strong vehicle to unlock the power of proteomics in the discovery and development of new diagnostics and therapeutics, both in academia and industry. With the first products moving into the markets it is an optimal time for me to join and help. I am impressed by what the people at AYOXXA have accomplished so far", says Dr Gerald Möller
